SANGAMO THERAPEUTICS, INC
SGMOQ · OTCMCIK 1001233fmd_0PA2E3EMHH7T13ZPF8XFE3K3Q7Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2009 to Mar 31, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 19 | 37 | 84 | 102 | 118 | 111 | 111 | 176 | 58 | 40 |
| Research and development | 66 | 66 | 115 | 146 | 181 | 231 | 250 | 234 | 112 | 113 |
| Total operating expenses | 92 | 93 | 162 | 208 | 248 | 294 | 313 | 450 | 162 | 161 |
| Operating income | (73) | (56) | (77) | (105) | (130) | (183) | (201) | (274) | (104) | (121) |
| Interest and investment income | 1 | 2 | 8 | 10 | 9 | 5 | 9 | 11 | 2 | 1 |
| Other non-operating income (expense) | 1 | – | – | – | – | – | – | – | 4 | (4) |
| Income before taxes | (72) | (55) | (69) | (95) | (121) | (178) | (192) | (263) | (98) | (124) |
| Income tax expense | (0) | 0 | 0 | 0 | 0 | 0 | 0 | (5) | (0) | (1) |
| Net income from continuing operations | (72) | (55) | (69) | (95) | (121) | (178) | (192) | (258) | (98) | (123) |
| Net income | (72) | (55) | (68) | (95) | (121) | (178) | (192) | (258) | (98) | (123) |